Objective: To assess whether a potential benefit with combination antibiotic therapy is restricted to the most critically ill subset of patients, particularly those with septic shock. Cochrane Central Register of Controlled Trials (to third quarter 2009), the ClinicalTrial.gov database, and the SCOPUS database.
A t the conclusion of this CME activity, participants should be able to select appropriate antibiotic regimens for patients with sepsis. Combination antimicrobial therapy is commonly used for the treatment of sepsis and septic shock. The most accepted rationale for this approach is the generation of an increased spectrum of coverage, even though current antimicrobials possess extremely broad activity. Assuming the pathogenic organism is susceptible to one antibiotic, the incremental benefit of combination therapy is uncertain. Although some animal models (1) (2) (3) and clinical studies of infection, including endocarditis, Gram-negative bacteremia, and neutropenic infections (4 -6) , support such combination therapy, the potential clinical benefit in other severe infections associated with sepsis and septic shock has been questioned. Two separate meta-analyses have failed to demonstrate evidence of improvement of outcome with combination therapy in immunocompetent patients with sepsis and/or Gramnegative bacteremia (7, 8) .
Meta-regression studies have found that efficacy of some medical therapies, including immunomodulatory therapy of sepsis, can be contingent on the underlying severity of illness and risk of death (9 -12) . A potential survival benefit with combination antimicrobial therapy may be similarly restricted to high-risk groups. A benefit in the most severely ill patients may be diluted or offset by less severely ill patients in whom no benefit exists or adverse effects of combination therapy dominate.
We report a meta-analysis/meta-regression study undertaken to determine whether combination antimicrobial therapy reduces mortality compared to monotherapy in patients with serious bacterial infections that can cause sepsis/septic shock. The specific hypothesis was that any beneficial effect of combination antimicrobial therapy on mortality of life-threatening infection is restricted to patients with septic shock or otherwise high-risk of death.
MATERIALS AND METHODS

Study Selection and Dataset Derivation
Both randomized and observational studies of antimicrobial therapy of serious bacterial infections potentially associated with sepsis and/or septic shock were included irrespective of causative organism, Gram stain characteristics, pres-ence of bacteremia, or specific clinical infection (as long as the primary cause of mortality in the infection was typically sepsis/septic shock). Sufficient data to calculate an odds ratio (OR) between single vs. combination antibiotic therapy had to be provided. Combination therapy was defined as a combination of two or more antibiotics of different antimicrobial class and mechanism of action (for example, two of three of a ␤-lactam, an aminoglycoside, or fluoroquinolones). The causative organism was required or, in the case of randomized trials, expected to be sensitive to both antimicrobials. Mortality and infection-related mortality were the primary outcome measures, although "clinical failure" was acceptable when mortality was not provided. Studies published in any language were reviewed.
Excluded were noninferiority studies comparing fixed regimens of a superior primary agent vs. an inferior agent of the same class with a second agent of a different class (because of the intrinsic, structural bias in such studies), investigations of endocarditis or meningitis (because the primary mechanism of death in these conditions is rarely sepsis/ septic shock), and trials restricted to neutropenic sepsis. Two independent reviewers performed the literature searches and identified relevant eligible studies. Final selection of studies was performed by consensus.
Data Sources
Relevant human studies were identified from OVID MEDLINE (1950 ( -October 2009 ). This search strategy was adapted to search EMBASE ( -October 2009 and the Cochrane Central Register of Controlled Trials (to third quarter 2009). The ClinicalTrial.gov database, the SCOPUS database, SIGLE (System for Information on Gray Literature), and Google Scholar were also utilized to search for relevant studies. Search terms included "sepsis," "septicemia," "septic shock," "severe sepsis," "bacterial pneumonia," "empyema," "bacteremia," "bloodstream infection," "peritonitis," "bowel perforation," "pyelonephritis," "urinary tract infection," "ischemic bowel," "bowel infarction," "entercolitis," "cellulitis," "necrotizing fasciitis," "cholangitis," "cholecystitis," "mediastinitis," and "abscess." These search terms were cross-referenced against "drug therapy, combination," "antibiotic," "monotherapy," or "combination therapy." References from relevant articles were reviewed to identify additional potentially eligible studies. 
Data Extraction and Modification
Whenever possible, relevant subgroups were extracted from published data. As a priority, eligible datasets were split into two mutually exclusive groups of septic shock and nonseptic shock or, if necessary, critically ill and noncritically ill. When the published dataset did not include this information, the primary study author of relevant studies was contacted to request these data. When possible, the monotherapy group was limited to ␤-lactams and/or fluoroquinolones (as the primary agent), and the combination therapy group required the same primary agent as part of the combination (to maximize comparability between the groups). Because of long-standing concerns regarding inferior results with aminoglycoside monotherapy, in particular, in the most severely ill (13, 14) , these cases were excluded when the dataset provided sufficient detail to allow extraction. Neutropenic, culture-negative, and atypical organism (mycoplasma, Legionella, viral) sepsis cases were also extracted when possible.
A standard form was used to extract pertinent data. Data were extracted by two independent reviewers. When analyzed data were extracted or modified from the original dataset, calculations were also performed independently by the two reviewers. Any disagreement between the two reviewers was resolved by consensus.
Statistical Analysis
Meta-Analysis. Pooled ORs and 95% confidence intervals (CIs) were calculated for each dataset. Pooled estimates of the OR and 95% CI were obtained using the random-effects model of DerSimonian and Laird (15) . Because most prospective clinical studies of severe sepsis inclusive of septic shock have yielded mortality risks of Ͼ25% and studies of sepsis without shock have yielded mortality risks of Ͻ15% (16 -18), eligible datasets were stratified (on an a priori basis) into three corresponding monotherapy mortality/ clinical failure rate groups of Ͻ15%, 15% to 25%, and Ͼ25%.
An OR of Ͻ1 signifies decreased mortality with combination therapy compared to monotherapy. Results were supported by application of fixed-effects models (15) . The analyses were performed using StatsDirect Software (Stats-Direct, Cheshire, UK). Testing for heterogeneity was performed using the I 2 statistic (19) . This statistic can be interpreted as the proportion of total variation across studies attributable to heterogeneity (min-max, 0%-100%). A funnel plot of the log of the OR against the sample size was performed to assess for potential selection biases, including publication bias (20) . Stratified subgroup analyses were also performed.
Meta-Regression.
Because the I 2 statistic indicated significant heterogeneity among the entire collection of datasets, metaregression was performed (21, 22) . Possible sources for heterogeneity including mortality rate in the reference (monotherapy) group were investigated.
To analyze the relationship between reference (monotherapy) mortality rate and the relative treatment effect, the log OR of death with combination therapy was plotted against the monotherapy mortality rate (x-axis) for each study. A linear meta-regression weighted to reflect the variance of the individual datasets was used to model the data. The mathematical model described the relationship between the log of the OR of death with combination therapy as a function of the mortality rate in the monotherapy arm. Supplemental meta-regressions were performed to examine the interactions of monotherapy mortality risk with major stratification groups. These analyses were performed using SAS PROC MIXED (v9.1.3; SAS Institute, Cary, NC).
RESULTS
Trial Characteristics
Fifty studies were found to be suitable for inclusion in this analysis (23-73) ( Fig.  1 ). Of the 1534 studies identified for initial examination, 59 were determined to potentially fit inclusion criteria after screening of published abstracts. Subsequently, nine studies were excluded after review of the article (4, 74 -81) . Of the 50 remaining eligible studies (23-73), 12 had data that could be split into mutually exclusive groups with differing severity of illness (25-29, 34, 42, 46, 54 -56,60) . Subset data for eight of these studies could be found in the original publication (25, 26, 28, 29, 34, 54, 55, 60) . The authors of four other published studies provided supplemental data from the origi-nal publication to separately analyze shock/nonshock cases (27, 42, 46, 56) . As a result, 62 distinct datasets were available for analysis ( Fig. 1 , Table 1 ).
Of the 12 split datasets, eight were split by presence or absence of shock (27, 28, 34, 42, 46, 54 -56) . The other four were split by a severity of illness scoring system (25, 26, 29, 60) . In addition, 17 datasets were modified by extraction of cases of aminoglycoside monotherapy (24, 30, 36, 37, 41, 45, 49 -52, 54, 62, 65, 70 -73) . Six studies and nine total datasets retained or potentially retained some cases of aminoglycoside monotherapy (29, 34, 38, 40, 60, 63) . Of the former, two studies had aminoglycoside monotherapy in approximately half the cases (29, 34) , with similar mortality outcome with aminoglycoside monotherapy and ␤-lactam monotherapy; another had a maximum of 15% of monotherapy with aminoglycosides (60), and frequency was undefined in one (63) . The inclusion of aminoglycoside treatment as monotherapy was uncertain in two studies (38, 40) . Four studies had culture negative and/or atypical organism cases extracted (25, 46, 59, 67) . Three studies had cases of neutropenic sepsis extracted (53, 67, 72) . Microbiological sensitivity of pathogens to antibacterials was confirmed in all included cases for all but 14 studies (19 datasets). In the remainder, it was inferred in at least some cases (24 -28, 33, 35, 44, 46, 48, 51, 59, 63, 64) . Twelve eligible studies (13 datasets) represented randomized, controlled trials (RCTs) (23, 33, 35, 39, 46, 48, 51, 53, 57-59, 62, 67) . The remaining studies were either prospective observational or retrospective cohort investigations (Table 1) . Table 1 summarizes the characteristics of the datasets utilized in this analysis. The number of evaluable cases of lifethreatening infection in the 50 eligible trials was 8504 patients (4553 monotherapy, 3951 combination therapy). Sample size among the different datasets ranged from 16 to 1111. Most studies primarily involved therapy with a ␤-lactam with or without an aminoglycoside, fluoroquinolone, or macrolide.
A Cook's D (influence diagnostic) test demonstrated that none of the datasets exceeds the critical value, i.e., none has a disproportionate impact on the results.
Meta-Analyses
Meta-analysis of the 62 eligible datasets demonstrated an estimated pooled OR for death/clinical failure of 0.856 (95% CI, 0.713-1.027) for combination compared to monotherapy regimens (p ϭ .094) ( Fig. 2 ). There was no evidence of a publication bias based on the Egger method (p ϭ .275). The shape of the funnel plot was symmetrical. However, there was statistically significant heterogeneity among the eligible datasets (Breslow-Day chi-square ϭ 125.03; df ϭ 61; p Ͻ .0001, I 2 ϭ 45.1%).
In Figure 2 , datasets are listed in sequential order of increasing monotherapy mortality/clinical failure rate. Although the pooled OR fails to demonstrate a significant advantage of combination therapy, there is a gradual trend of the individual OR positions switching from the right (favoring monotherapy) to the left (favoring combination therapy) as monotherapy mortality/clinical failure rate increases. Stratification of the dataset by monotherapy mortality/clinical failure rate confirms this observation. The pooled OR for datasets when the monotherapy mortality/clinical failure rate is Ͻ15% significantly favors monotherapy (OR, 1.53; 95% CI, 1.16 -2.03; p ϭ .003; I 2 ϭ 8.2%). The pooled OR for monotherapy mortality/clinical failure rate of 15% to 25% indicates no difference in efficacy of monotherapy or combination therapy (OR, 1.05; 95% CI, 0.81-1.34; p ϭ .7657; I 2 ϭ 30.7%). However, combination therapy demonstrates a significant advantage over monotherapy when the rate of death/clinical failure exceeds 25% (pooled OR, 0.54; 95% CI, 0.45-0.66; p Ͻ .0001; I 2 ϭ 0%). Stratification of datasets results in a marked decrease in heterogeneity in all stratified groups, suggesting that variations in mortality/ CAP, community-acquired pneumonia; VAP, ventilator-associated pneumonia; AG, aminoglycoside; FQ, fluoroquinolones; ESBL, extended-spectrum ␤-lactamase; RCT, randomized controlled trial; RCS, retrospective cohort study; POS, prospective observational study. a Nonshock or shock or noncritically ill stratified dataset; b Shock or critically ill stratified dataset; c Modified dataset provided by study authors. clinical failure risk represents a substantial portion of the heterogeneity in the aggregate meta-analysis. No other stratification resulted in a similar decrease of I 2 in all strata ( Table 2 ). The 12 studies that were stratified into septic shock/critically ill and nonseptic shock/noncritically ill datasets were examined ( Fig. 3) . Pooled ORs for the eight studies split by the presence or absence of shock (27,28,34,42,46,54 -56) and the four studies split by the presence or absence of critical illness (25, 26, 29, 60) demonstrated a significant advantage to combination therapy in the more ill group but did not demonstrate evidence of a similar trend in the less ill groups. Consolidation of the combined shock and critically ill datasets demonstrated similar results (OR, 0.51; 95% CI, 0.36 -0.72; p ϭ .0002; I 2 ϭ 0%). Pooled ORs for the consolidated nonshock/noncritically ill show an absence of any beneficial effect with combination therapy (OR, 1.06; 95% CI, 0.76 -1.47; p ϭ .7178; I 2 ϭ 19.1%). Consolidation of all datasets yields a trend toward superiority of combination therapy that fails to reach significance (OR, 0.76; 95% CI, 0.57-1.02; p ϭ .0622; I 2 ϭ 33.8%). The I 2 value for study heterogeneity is substantially reduced by splitting the 12 datasets into shock/ critically ill and nonshock/noncritically ill groups. As can be seen by examination of the datasets used in this analysis (25-29, 34, 42, 46, 54 -56, 60) in Figure 2 , the OR describing mortality/clinical failure with combination therapy for the septic shock or otherwise more critically ill subset of the individual datasets was shifted to the left (i.e., favoring combination therapy) relative to the matching nonseptic shock/noncritically ill dataset in 10 of the 12 datasets excluding only the studies of Harbarth et al (42) and Garnacho-Montero et al (55) .
To further examine statistical heterogeneity in the aggregate meta-analysis and potential sources of variation in individual dataset results, additional stratified meta-analyses were performed ( Table  2) . Observational (non-RCT) studies (49 datasets) demonstrate a high level of heterogeneity and fail to show evidence of a benefit of combination therapy. A similar lack of evidence of efficacy is apparent whether examining prospective observational data (15 datasets) or retrospective cohort studies (34 datasets) ( Tables 1 and  2 ). RCTs (13 datasets) demonstrate no significant benefit of a combination strategy despite low heterogeneity (Tables 1  and 2 ). Exploratory subgroup analyses to determine whether findings would differ by limiting the analysis to studies published during or before 1992 (29 datasets) or during or after 1993 (33 datasets), when more potent antimicrobials became available for serious infection demonstrated similar results (Tables 1 and 2) .
Stratification by other criteria including use of ␤-lactam as sole primary therapy, aminoglycosides as the sole secondary agent, clinical syndrome (bacteremia, nonbacteremia, community-acquired pneumonia, hospital-acquired pneumonia/ventilator-associated pneumonia), Gram stain characteristic of pathogen, specific pathogen (Pseudomonas, Klebsiella, Streptococcus pneumoniae), and end point (hospital mortality, 7-to 30day mortality, clinical failure) also showed no significant reduction in heter- Figure 2 . Analysis of studies comparing combination antibiotic therapy with monotherapy for reducing mortality of life-threatening infections associated with sepsis. Note the gradual shift of the odds ratio from the right to the left as monotherapy mortality increases. The size of the squares is proportional to the reciprocal of the variance of the studies. a , Nonshock or noncritically ill stratified dataset. b , Shock or critically ill stratified dataset. c , Modified dataset provided by study authors. Figure 4 plots the OR of death with combination therapy (y-axis) against the mortality/clinical failure rate with monotherapy in individual datasets (x-axis). There is a significant negative slope (OR, 1.304; 95% CI, 1.205-1.412; p Ͻ .0001 per 10% increase in reference group mortality), suggesting that the probability of a beneficial effect with combination therapy increases with increasing risk of death/clinical failure in the monotherapy arm. A random-effects meta-regression (OR, 1.318; 95% CI, 1.190 -1.460; p Ͻ .0001 per 10% increase in monotherapy group mortality) and meta-regression using the aggregate mortality of the complete datasets (i.e., both monotherapy and combination therapy groups together) in place of the monotherapy group mortality as the independent variable (OR, 1.173; 95% CI, 1.070 -1.285; p Ͻ .0001 per 10% increase in aggregate mortality) performed to address the issue of regression to the mean yielded similar results (21, 82, 83) .
Meta-Regression
In Figure 4 , the intersection of the 95% CI lines with the x-axis shows a statistically significant benefit with combination therapy begins as monotherapy mortality rate exceeds 25% (OR at 26%, 0.881; CI, 0.780 -0.994; p ϭ .0447). In contrast, monotherapy is statistically favored at a monotherapy mortality risk of 15% or lower (OR at 15%, 1.180; CI, 1.017-1.3681; p ϭ .0334).
A similar trend is seen if the metaregression is restricted to either observational studies (Fig. 5A) or RCTs (Fig. 5B) . Figure 3 . Subset analysis comparing combination antibiotic therapy with monotherapy for reducing mortality of life-threatening infections associated with sepsis in shock/critically ill and nonshock/ noncritically ill patient datasets (derived from 12 studies in which groups could be separated; see Table 1 ).
Figure 4. Meta-regression of all datasets. The weighted meta-regression line (with 95% confidence interval)
shows the relationship between the log odds ratio of death/clinical failure with combination therapy and the mortality/clinical failure rate in the reference (monotherapy) group for all eligible datasets. Closed circles represent nonrandomized observational datasets (n ϭ 44), whereas open inverted triangles represent randomized, controlled study datasets (n ϭ 12). The size of the symbols is inversely proportional to the variance of each dataset. The negative slope of the regression line indicates a significant positive relationship between the probability of benefit of combination therapy and increasing risk of death/clinical failure in the reference (monotherapy) group (odds ratio, 1.304; 95% confidence interval, 1.205-1.412; p Ͻ .0001 per 10% increase in reference group mortality). Combination therapy appears to hold a significant advantage at reference group mortality/clinical failure rates of Ͼ25% (as indicated by the crossing of the upper 95% confidence interval line through a log odds ratio value of 1). However, combination therapy appears to confer a significant disadvantage at reference group mortality rates of Յ15%. Rx, therapy; AG, aminoglycoside. a Change in log of the odds ratio of the probability of benefit with combination therapy with every 10% increase in mortality risk of the reference (monotherapy) group; b Datasets with an n Յ 25 in either monotherapy or combination therapy arm excluded; c Primary agent other than ␤-lactam only (i.e., a mix of ␤-lactams and other antibiotics); d Secondary agent other than only aminoglycoside; e Secondary agents not specifically defined (may include aminoglycosides, fluoroquinolones, macrolides, or others). Note that number of datasets for meta-regression may be smaller than those used for meta-analysis because of the fact that meta-regression did not include studies when the estimate effect was infinite (i.e., 0% or 100% mortality in either arm).
In addition, Table 2 contains a series of meta-regressions for subgroups. In almost every case, there is at least a trend suggesting increasing benefit with combination antimicrobial therapy as the monotherapy mortality rate increases. This effect holds whether hospital mortality, 7-to 30-day mortality, or clinical failure is used as the study end point. Further, Table 3 shows the OR intercepts at 0% and 100% mortality in the monotherapy reference group for each subgroup. Notably, whenever there is a significant meta-regression slope in Table 2 , the intercept for 0% and 100% reference group mortality is always more than one and less than one, respectively. This indicates a trend toward harm and benefit, respectively, at low and high mortality risk in each subgroup (even if the range of the 95% CI included 1.0 in some cases).
These analyses indicate that a substantial amount of heterogeneity in the OR of death/clinical failure with combination therapy is accounted for by the mortality rate of the monotherapy group. Addition of variables for other potential sources of heterogeneity and the interaction between these and monotherapy mortality rate were uniformly found to be nonsignificant (p Ͼ .20). These other variables included, most notably, the presence or absence of an RCT study design. In addition, Gram stain character, bacteremia, pulmonary site of infection, Ͼ10% patients with neutropenia, microbiological proof of antibiotic sensitivity, use of ␤-lactam as primary therapy, and use of aminoglycoside as secondary therapy were also not significant in the model. Inclusion in the meta-regression of year of publication and use of mortality vs. clinical failure end point yielded similar negative results. Only monotherapy mortality rate was associated with probability of benefit with combination therapy in these analyses.
DISCUSSION
Our results indicate, in contrast to previous meta-analytic studies (7, 8) , that combination anti-infective therapy reduces mortality in patients with serious bacterial infections, but only in those at the highest risk for death (Fig. 2) . The analysis of those studies that could be split into septic shock and nonshock strata (27, 28, 34, 42, 46, 54 -56) suggests that the beneficial effect may be entirely restricted to septic shock cases (Fig. 3) .
Our conclusions regarding the importance of mortality risk in relation to the potential benefit of combination therapy is strongly supported by the metaregression results (Fig. 4 , Table 2 ). The data clearly suggest that there is a statistically significant benefit of combination therapy at mortality/clinical failure risk of Ͼ25%, but that this benefit disappears in the 15% to 25% risk range. In fact, combination therapy appears to be associated with worse survival if the reference (monotherapy) risk is 15% or less. The meta-regression also confirms that no assessed factor other than monotherapy mortality risk makes a statistically significant contribution to the model. Notably, our meta-regression results held individually in both RCT and non-RCT subgroups ( Fig. 5 , Table 2 ).
Several potential explanations for a differential impact of combination and monotherapy at varying mortality risks exist. The underlying hypothesis driving this analysis was that the evolution of septic shock is based, in part, on an increasing microbial burden relative to less severe illness (84, 85) and that persistence of shock results in a marked timedependent increased risk of death (86, 87) . Accelerated pathogen clearance in septic shock should presumably result in more rapid establishment of hemodynamic stability and improved survival. Combination therapy, particularly with ␤-lactams in combination with aminoglycosides (88 -91) , fluoroquinolones (92) (93) (94) (95) (96) (97) (98) , and macrolides (99 -102) , has demonstrated evidence of synergism (i.e., accelerated pathogen clearance) in exper- Figure 5 . Meta-regression of non-randomized control trial (non-RCT) (A) and RCT datasets (B). The weighted meta-regression line (with 95% confidence interval) shows the relationship between the log odds ratio of death/clinical failure with combination therapy and the mortality/clinical failure rate in the reference (monotherapy) group for each group of datasets. Closed circles represent nonrandomized observational datasets (n ϭ 44), whereas open inverted triangles represent randomized, controlled study datasets (n ϭ 12). The size of the symbols is inversely proportional to the variance of each dataset. Both datasets show a similar negative slope indicating a significant positive relationship between the probability of benefit of combination therapy and increasing risk of death/clinical failure in the reference (monotherapy) group. For the non-RCT datasets, the negative slope of the regression line indicates an odds ratio of 1.475 (95% confidence interval, 1.385-1.569; p Ͻ .0001 per 10% increase in reference group mortality). Based on the 95% confidence interval, mortality/clinical failure rates in the reference group of Ͼ26% or Ͻ15% indicated significant benefit or harm respectively from combination therapy. For the RCT datasets, the regression line indicates an odds ratio of 1.425 (95% confidence interval, 1.121-1.811; p Ͻ .0001 per 10% increase in reference group mortality). Mortality/clinical failure rates of Ն35% suggested significant benefit with combination therapy, but a trend toward harm at lower risk levels did not reach significance.
imental studies. Given the larger proportion of septic shock cases likely to exist in the high-risk mortality groups, any benefit of combination therapy would be ex-pected to be disproportionately high in such groups.
Immunomodulatory effects of the supplemental agent could also provide a greater benefit to sicker patients in view of the greater inflammatory responses seen in septic shock patients (103, 104) . Potentially salutary immunomodulatory activity has been suggested with macrolides (105-109) but has also been described with fluoroquinolones (106, 110, 111) . Despite this, clinically relevant immunomodulatory activity of the secondary agent would seem to be less likely because beneficial effects would not be expected to be seen with several different antibiotic groups, particularly aminoglycosides.
The design of this study removes the potential benefit of providing a broader range of coverage for microbial pathogens with combination therapy by excluding or eliminating culture-negative cases (when possible) and retaining only studies with inferred or confirmed pathogen sensitivity to utilized antimicrobials. Notably, restriction of the dataset to studies with confirmed microbiological sensitivity (Table 2) showed the same variation in impact of combination therapy with mortality risk as the overall group.
The mechanism underlying the apparent survival disadvantage in lower-risk patients treated with combination therapy is unknown. Drug toxicity (13, 110) would seem to be most likely, but possible antibiotic antagonism (112) and the development of resistant organisms (113) could each play a role.
Because the individual studies encompassed in our study are substantially identical to those in earlier meta-analyses indicating an absence of any benefit of combination therapy (7, 8) , the reason for the divergent conclusions must be addressed. The basis of the divergence appears to be differences in handling of the individual datasets. Previous metaanalytic investigations have attempted to minimize heterogeneity by focusing on specific clinical syndromes, organism groups, and study designs. We opted to maximize our sample size by including a wide variety of organisms, clinical syndromes, and types of studies. However, heterogeneity was limited by excluding most noninferiority studies because of their intrinsic structural bias toward regimen equivalence. In addition, when possible, datasets were modified to focus on ␤-lactam and/or fluoroquinolone monotherapy in comparison to a similar regimen supplemented with the addition of a secondary agent (aminoglycoside, fluoroquinolones, or macrolides). To further minimize heterogeneity, we extracted or excluded culture-negative and neutropenic cases when that was an option. Perhaps most importantly, we were able to split 12 of the study datasets into mutu-ally exclusive shock/critically ill and nonshock/noncritically ill components. This had the effect of increasing the potential underlying signal. The result of these maneuvers was apparent in the monotherapy mortality stratified meta-analysis in which the benefit of combination antibiotic therapy is shown to be highly dependent on baseline (monotherapy) mortality risk and in the split studies that demonstrate that combination therapy benefits those groups of patients with septic shock or critical illness based on severity scoring.
Our analysis has significant limitations. Few of the included studies were randomized trials; most studies were observational, using a variety of antiinfectives for varying durations in nonstandardized schedules. In these observational studies, the effect of unidentified confounding factors or residual confounding for known factors cannot be ruled out. Note that although we attempted to use an alternate indicator of severity of illness in the analysis in place of monotherapy mortality, most studies did not stratify outcome by severity of illness. This may be important because combination therapy may more likely to be administered in either the sickest patients who are more likely to die or, alternately, less likely to be administered to such patients because of concurrent organ failure, which may increase risk of drug toxicity. For example, Paul et al (78) have demonstrated that an apparent advantage of combination therapy (␤lactam with or without macrolides) in unadjusted data for hospitalized community-acquired pneumonia is eliminated in a propensity-adjusted analysis. The inability to adjust for confounding covariates in most of the nonrandomized cohort studies precludes drawing strong conclusions regarding our findings. However, the fact that meta-regression results held in the RCT subset of studies (Table  2 ) supports the validity of the central observation across the entire study dataset.
In conclusion, our study suggests that a survival benefit of combination antibiotic therapy in serious bacterial infections associated with sepsis is restricted to the most severely ill subset of patients with septic shock and/or a projected mortality/clinical failure rate of Ͼ25% (in the absence of combination therapy). Notably, our data also suggest the possibility that combination therapy may be associated with increased risk of death in pa-tients with low mortality risk (Յ15%). The presence of septic shock may be a simple prospective method to identify patients who may benefit from combination therapy. Alternately, severity of illness scoring systems could be used to identify patients most likely to benefit. At the conclusion of this CME activity, participants should be able to select appropriate antibiotic regimens for patients with sepsis.
